Epistem licence Hubrecht Organoid Technology to expand pre-clinical toxicology service portfolio Read more
FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101) Read more
AM-Pharma Raises €116m [$133m] to Conduct Pivotal Phase III Trial of recAP in Acute Kidney Injury Read more
Kite Announces Plans to Bolster Industry-Leading Cell Therapy Manufacturing Capabilities With New Viral Vector Facility Read more
Sosei Heptares Enters Into Multi-target Research Collaboration and License Agreement With Genentech Read more
Exclusive interview with AstraZeneca ahead of upcoming Wearable Injectors & Connected Devices Read more
Dicerna Receives Breakthrough Therapy Designation for DCR-PHXC for Treatment of Primary Hyperoxaluria Type 1 (PH1) Read more